Introduction
A common feature among a number of neurological disorders is the abnormal aggregation of a natively soluble protein, as observed for amyloid b in Alzheimer's disease (AD) [1] and huntingtin protein in Huntington's disease [2] . Similarly, a particular group of neurodegenerative disorders is characterized by abnormal accumulation of a-synuclein (a-syn); termed the a-synucleinopathies, this group includes Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) [3] . Although PD and DLB have attracted much scientific attention in recent years, research into MSA has continued in the relative background. A stark indication of the relative levels of research being conducted into these different disorders is evident from a simple PubMed search, which recently returned close to 60 000 results when searching for 'Parkinson's disease' but a mere 3765 results for 'multiple system atrophy'. However, despite this apparent underrepresentation of MSA, a considerable amount of progress has been made in this field, largely owing to cross-disease application of the understanding of key neurodegenerative pathways and, in particular, the pathological role of a-syn.
This review focuses on MSA and describes recent efforts to improve the clinical diagnosis of this disorder and the impact that transgenic animal models have had on unraveling key pathological mechanisms underlying the disease.
Finally, we discuss how a greater understanding of these mechanisms is advancing the development of diseasemodifying therapeutic interventions.
Clinicopathological characteristics of MSA
The term MSA was coined in 1969 to encompass three previously distinct neurodegenerative disorders, striatonigral degeneration, olivopontocerebellar ataxia and ShyDrager syndrome [4] . MSA is a progressive neurodegenerative disorder with an estimated annual worldwide incidence of approximately 0.6/100 000, which increases to 3/ 100 000 in the population >50 years [5] [6] [7] . The mean age of disease onset is approximately 60 years and mean survival ranges from 7 to 9 years following the appearance of clinical symptoms [8] . Since its initial classification as a single, albeit pleomorphic, disease entity, a great deal of research has focused on understanding the clinical characteristics of MSA (Figure 1) .
MSA is characterized clinically by symptoms that can be subdivided into pyramidal, extrapyramidal, cerebellar and autonomic categories. Extrapyramidal motor abnormalities such as bradykinesia, rigidity and postural instability are classed as either parkinsonian-type (MSA-P) or cerebellar (MSA-C) and reflect damage to the basal ganglia (striatonigral degeneration) or cerebellum (olivopontocerebellar atrophy), respectively [6, [9] [10] [11] [12] [13] . In addition, MSA patients develop behavioral alterations such as depression and executive dysfunction that suggest frontal lobe impairment [14] [15] [16] [17] [18] . Recent epidemiological studies in North America [6] and Japan [19] have suggested ethnic variation with regard to the incidence of MSA-P or MSA-C. The North American study found that 60% of the study patients had MSA-P and 13% had MSA-C [6] . By contrast, in the Japanese study a much higher percentage of patients (83.8%) had MSA-C features and only 16.2% of patients were categorized as MSA-P [19] . The underlying cause of this variability remains undetermined but may involve genetic or environmental factors, or a combination thereof. Autonomic dysfunction, most commonly urogenital, gastrointestinal and cardiovascular dysfunction in the form of orthostatic hypotension, eventually develops in both MSA-P and MSA-C patients [20] .
Current therapeutic interventions for MSA are aimed at the treatment of symptoms such as hypotension, erectile dysfunction and gastrointestinal dysfunction rather than at the underlying pathology itself [21-25]. Many MSA-P patients present with symptoms resembling PD, including 
